OncoSil Medical Limited (ASX:OSL)

OncoSil Medical Statistics

Total Valuation

OncoSil Medical has a market cap or net worth of AUD 15.47 million. The enterprise value is 12.66 million.

Market Cap	15.47M
Enterprise Value	12.66M

Important Dates

The next estimated earnings date is Tuesday, March 3, 2026.

Earnings Date	Mar 3, 2026
Ex-Dividend Date	n/a

Share Statistics

OncoSil Medical has 23.62 million shares outstanding. The number of shares has increased by 97.77% in one year.

Current Share Class	23.62M
Shares Outstanding	23.62M
Shares Change (YoY)	+97.77%
Shares Change (QoQ)	+19.93%
Owned by Insiders (%)	6.29%
Owned by Institutions (%)	24.62%
Float	21.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.15
PB Ratio	4.03
P/TBV Ratio	4.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.98
EV / Sales	3.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.98

Financial Position

The company has a current ratio of 2.05, with a Debt / Equity ratio of 0.01.

Current Ratio	2.05
Quick Ratio	1.86
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.00
Interest Coverage	-688.06

Financial Efficiency

Return on equity (ROE) is -208.41% and return on invested capital (ROIC) is -129.74%.

Return on Equity (ROE)	-208.41%
Return on Assets (ROA)	-87.11%
Return on Invested Capital (ROIC)	-129.74%
Return on Capital Employed (ROCE)	-337.60%
Weighted Average Cost of Capital (WACC)	11.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.40
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -72.71% in the last 52 weeks. The beta is 1.23, so OncoSil Medical's price volatility has been higher than the market average.

Beta (5Y)	1.23
52-Week Price Change	-72.71%
50-Day Moving Average	0.85
200-Day Moving Average	1.18
Relative Strength Index (RSI)	33.81
Average Volume (20 Days)	87,234

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OncoSil Medical had revenue of AUD 3.72 million and -12.92 million in losses. Loss per share was -0.85.

Revenue	3.72M
Gross Profit	1.07M
Operating Income	-12.98M
Pretax Income	-12.92M
Net Income	-12.92M
EBITDA	-12.98M
EBIT	-12.98M
Loss Per Share	-0.85

Balance Sheet

The company has 2.85 million in cash and 42,469 in debt, with a net cash position of 2.81 million or 0.12 per share.

Cash & Cash Equivalents	2.85M
Total Debt	42,469
Net Cash	2.81M
Net Cash Per Share	0.12
Equity (Book Value)	3.84M
Book Value Per Share	0.20
Working Capital	3.45M

Cash Flow

In the last 12 months, operating cash flow was -12.91 million and capital expenditures -6,561, giving a free cash flow of -12.91 million.

Operating Cash Flow	-12.91M
Capital Expenditures	-6,561
Free Cash Flow	-12.91M
FCF Per Share	-0.55

Margins

Gross Margin	28.83%
Operating Margin	-348.58%
Pretax Margin	-346.80%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OncoSil Medical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-97.77%
Shareholder Yield	-97.77%
Earnings Yield	-83.51%
FCF Yield	-83.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 3, 2025. It was a reverse split with a ratio of 0.0025.

Last Split Date	Jun 3, 2025
Split Type	Reverse
Split Ratio	0.0025

Scores

OncoSil Medical has an Altman Z-Score of -22.57 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-22.57
Piotroski F-Score	3